Dupilumab improves the molecular signature in skin of patients with moderate-to-severe atopic dermatitis.

• Results Overview

  Dupilumab treatment improved the molecular markers of atopic dermatitis in skin samples, showing that it effectively targets and reduces inflammation associated with the condition.

• Study Summary

  Num Participants:

  None

  Study Type:

  Rct

  Control Group:

  Placebo

  Efficacy End Points Treatment:

  {'Upregulated genes decrease (300mg)': 65, 'Downregulated genes increase (300mg)': 32}

  Efficacy End Points Control:

  {'Gene expression': 'Worsening of AD transcriptome'}

  Side Effects Treatment:

  Adverse Event	Severity	Percentage Affected

  Side Effects Control:

  Adverse Event	Severity	Percentage Affected